Table 1 Patients and treatment characteristics

No

%

Age (years)

Median (range)

73 (54–92)

Sex

Male

100

58

Female

72

42

T stage

IA (T1a-c)

110

64

IB (T2a)

39

23

IIA (T2b)

23

13

Pathologic confirmation

Yes ( spino/adeno)

82 (44/70)

48

No

90

52

PET

Yes

105

61

No

67

39

COPD (GOLD)

0

43

25

1

23

13

2

42

24

3

37

22

4

27

16

FEV1% predicted

Median (range)

55% (20–137)

≥ 50%

108

63

< 50%

64

37

AACCI

Median (range)

5 points (2-10)

2–5

114

66

6–10

58

34

Performance Status

0

45

26

1

88

51

2

39

23

Tumor location

Central

23

13

Peripheral

149

87

Dose fractionation

60–54 Gy/3fr.

92

53

30–33 Gy/1fr.

19

11

60–55 Gy/5fr.

42

24

50 Gy/5fr.

19

11

BED₁₀prescribed

Median (range)

151.2 (94–180)

≥ 151.2 Gy

82

48

< 151.2 Gy

90

52

BED₁₀maximum

Median (range)

251.6 (135–398)

≥ 251.6 Gy

75

44

< 251.6 Gy

97

56